About iTP

iTP Biomedica Corporation

iTP Biomedica Corporation develops diagnostic tools for cancers and other complex diseases. Typical diagnostic tests analyze the activity of a small number of genes, which limits their clinical utility in determining disease behaviour.

iTP Biomedica’s approach is different. We employ next generation sequencing to measure the activity of all genes. Our comprehensive analysis of RNA, which is the functional output of the genome, provides unprecedented insight into disease severity. iTP’s technology platform represents a massive step forward in helping doctors better understand and manage disease.

iTP Biomedica’s state-of-the-art technology platform has initially been used to develop BladderPredict™, which uses the molecular fingerprint of early stage bladder cancer to characterize the disease.  This could assist physicians in managing their patients’ treatment for the best outcomes.


Milestones at a Glance



  • iTP’s clinical laboratory supplier receives College of American Pathologists (CAP) Laboratory Accreditation, including iTP’s technology in the review.
  • BladderProgress™ being developed to better predict which patients with non-muscle invasive high grade tumours will respond to front line treatment (BCG – Bacillus Calmette-Guerin).


  • BladderPredict™ developed to provide a molecular classifier of non-muscle invasive bladder cancer.
  • Funding received from the Government of Ontario’s OCE’s Market Readiness CC (MRII) program.
  • iTP Biomedica through its clinical laboratory supplier receives ISO15189 accreditation allowing iTP products to be supported.


  • iTP Biomedica established and initially funded by Mount Sinai Hospital’s Lunenfield-Tanenbaum Research Institute (LTRI) and by Mount Sinai Services, both world renowned for cancer diagnoses and care.
  • Leadership team established.
  • Bladder Cancer targeted as first indication given unmet medical need.


ITP Biomedica Differentiators


Innovative, state-of-the-art laboratory practices. Technology platform examines massive datasets, allowing for unprecedented depth in understanding disease.

Diagnostic approach is rapidly transferable to multiple cancers and complex diseases.

Spun out of Mount Sinai Hospital’s Lunenfield-Tanenbaum Research Institute (LTRI), world renowned for cancer diagnosis and care.

Leadership team with global business experience, expertise in transcriptomics, analyzing clinical data sets and research excellence.


Dr. Ken Hughes, CEO


Dr. Jeff Wrana, CSO


Dr. Alexandre Zlotta, CMO


Dr. Azar Azad, COO

Our Partners